EGFR and non-small cell lung carcinoma: Of note, preclinical experiments indicate that BH3-mimetics or HDAC-inhibitors, such as vorinostat, can restore BIM functionality and sensitivity to EGFR-TKIs in EGFRM+ NSCLC cells carrying the BIM polymorphism [221,222,223].